REXAHN PHARMACEUTICALS, INC. 4
4 · REXAHN PHARMACEUTICALS, INC. · Filed Jan 12, 2015
Insider Transaction Report
Form 4
Jeong Tae Heum
DirectorCFO
Transactions
- Exercise/Conversion
Common Stock
2015-01-12$0.80/sh+49,800$39,840→ 554,800 total - Exercise/Conversion
Stock Option (right to purchase)
2015-01-12−49,800→ 182,728 totalExercise: $0.80Exp: 2015-01-20→ Common Stock (49,800 underlying) - Sale
Common Stock
2015-01-12$0.91/sh−49,800$45,492→ 505,000 total - Exercise/Conversion
Stock Option (right to purchase)
2015-01-09−188,690→ 232,528 totalExercise: $0.80Exp: 2015-01-20→ Common Stock (188,690 underlying) - Sale
Common Stock
2015-01-09$0.92/sh−188,690$172,708→ 505,000 total - Sale
Common Stock
2015-01-08$0.90/sh−78,782$70,935→ 505,000 total - Exercise/Conversion
Common Stock
2015-01-09$0.80/sh+188,690$150,952→ 693,690 total - Exercise/Conversion
Stock Option (right to purchase)
2015-01-08−78,782→ 421,218 totalExercise: $0.80Exp: 2015-01-20→ Common Stock (78,782 underlying) - Exercise/Conversion
Common Stock
2015-01-08$0.80/sh+78,782$63,026→ 583,782 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price of $0.9004 per share represents a weighted average of sales prices from $0.90 to $0.9088 per share. The reporting person undertakes to provide upon request of the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price of $0.9153 per share represents a weighted average of sales prices from $0.90 to $0.945 per share. The reporting person undertakes to provide upon request of the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The price of $0.9135 per share represents a weighted average of sales prices from $0.90 to $0.9325 per share. The reporting person undertakes to provide upon request of the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]Options vested and became exercisable based on the following schedule: 150,000 on January 20, 2006, 150,000 on January 20, 2007, and 200,000 on January 20, 2008.